Preclinical News and Research

RSS

EntreMed receives new patent for 2-Methoxyestradiol analogs

EntreMed, Inc. has announced the issuance of U.S. Patent No. 7,371,741 covering analogs of 2- methoxyestradiol (2ME2).

11 Jun 2008

Maxygen receives approval for trial of factor VIIa in UK

Maxygen, Inc. today announced that it has filed a Clinical Trial Authorization (CTA) and received the necessary approvals in the United Kingdom to initiate a first-in-human Phase I trial of MAXY-VII in hemophilia patients.

11 Jun 2008

Synthetic molecules developed by Hebrew University researchers hold promise for new family of anti-cancer drugs

Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.

4 Jun 2008

Prostate Cancer Foundation 'beefs up' cancer research

The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program, this week.

4 Jun 2008

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

CSL Behring today presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.

3 Jun 2008

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).

3 Jun 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

Researchers pinpoint gene mutations responsible for 10 percent of non-familial cases of schizophrenia

Scans of the genome of patients with schizophrenia have revealed rare spontaneous copy number mutations that account for at least 10 percent of the non-familial cases of the disease.

1 Jun 2008

Fireflies' glow helps researchers track cancer drug's effectiveness

The gene that allows fireflies to flash is helping researchers track the effectiveness of anti-cancer drugs over time.

29 May 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Chemically modified protein may help people with hard-to-treat hemophilia

Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A. The discovery and the results of pre-clinical tests appear in the May 2 issue of the Journal of Biological Chemistry.

19 May 2008

Cancer drug shows promise as treatment for pulmonary hypertension

A drug developed to fight cancer is showing early promise as a treatment for pulmonary hypertension, researchers from the University of Chicago Medical Center report May 19 at the American Thoracic Society International Conference in Toronto, Canada.

19 May 2008

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and Cancer Research Technology (CRT) - the charity's development and commercialisation arm - today announced an innovative new arrangement to progress into clinical development a potential anti-cancer compound from AstraZeneca.

19 May 2008

Pfizer and Peter MacCallum support the future of cancer research in Australia

Australia's reputation for excellence in cancer research has been strengthened with the launch of the Peter MacCallum Pfizer Translational Oncology Research Collaborative Hub (TORCH) at the Peter MacCallum Cancer Centre, by the Minister for Innovation, Industry, Science and Research, Senator the Hon. Kim Carr.

18 May 2008

DNA vaccines boosted by dendritic cells

The concept sounds ideal: vaccines made of DNA that could be taken in by other cells and give instructions for how to fight off different diseases. The reality, however, has fallen short. Although DNA vaccines have been around for about 15 years and shown lots of promise for HIV, SARS and influenza vaccines during preclinical testing in mice, researchers have yet to make them potent enough to be helpful in humans.

18 May 2008

microRNAs provide more clues to genetics of schizophrenia

Researchers at Columbia University Medical Center have illuminated a window into how abnormalities in microRNAs, a family of molecules that regulate expression of numerous genes, may contribute to the behavioral and neuronal deficits associated with schizophrenia and possibly other brain disorders.

11 May 2008

Cytopia announces novel anti-cancer drug development collaboration

Cytopia Limited today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.

9 May 2008

Patent claims allowed covering Samaritan's Alzheimer's memory recovery drug in Australia

Samaritan Pharmaceuticals, a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office.

6 May 2008

Geron Corporation awarded UK grant funding for human embryonic stem cell research

Geron Corporation announced today two grant awards to the University of Edinburgh from the UK Stem Cell Foundation, with funding from the Medical Research Council and Scottish Enterprise.

6 May 2008

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.

6 May 2008

Preclinical News and Research

EntreMed receives new patent for 2-Methoxyestradiol analogs

Maxygen receives approval for trial of factor VIIa in UK

Synthetic molecules developed by Hebrew University researchers hold promise for new family of anti-cancer drugs

Prostate Cancer Foundation 'beefs up' cancer research

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

Medarex announces preliminary data for investigational anti-PD-1 antibody

Researchers pinpoint gene mutations responsible for 10 percent of non-familial cases of schizophrenia

Fireflies' glow helps researchers track cancer drug's effectiveness

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

Chemically modified protein may help people with hard-to-treat hemophilia

Cancer drug shows promise as treatment for pulmonary hypertension

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Pfizer and Peter MacCallum support the future of cancer research in Australia

DNA vaccines boosted by dendritic cells

microRNAs provide more clues to genetics of schizophrenia

Cytopia announces novel anti-cancer drug development collaboration

Patent claims allowed covering Samaritan's Alzheimer's memory recovery drug in Australia

Geron Corporation awarded UK grant funding for human embryonic stem cell research

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News